Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALCIFADE trial of etidronate in Fahr's disease or Fahr's syndrome
2024-512300-19-00Phase 2Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in idiopathic basal ganglia calcification (PFBC) comparing Etidronate disodium with Placebo (2 arms). Primary endpoint: Change in cognitive functioning. Planned start Oct 2024; status: authorised.
02
Drugs
etidronate
03
Conditions
idiopathic basal ganglia calcification (PFBC)
Beyond the preview
Go deeper on 2024-512300-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512300-19-00.